CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Vascular Flow Technologies Limited on the restructuring of £7,000,000 in outstanding loan notes into Series A Ordinary Preference shares as well as the concurrent closing of a £3,000,000 Series B financing round. The Series B round was led by an undisclosed family office and supported by institutional and individual angel investors.
Vascular Flow Technologies (Dundee, United Kingdom) is focused on the research, development and commercialisation of devices to improve blood flow in compromised or diseased blood vessels utilizing its proprietary Spiral Laminar Flow technology. Natural blood flow has a distinctive singular spiral flow pattern and the patented Spiral Laminar Flow technology is the only clinically‐proven design to replicate this. The Company has two CE-marked and FDA approved devices commercialised in Europe and the US. The Spiral Laminar Flow technology is used to create a longer lasting graft or stent, producing a better quality-of-life for the patient due to reduced vascular complications and improved longevity of the implant. Further information is available at www.vascular‐flow.com.
CATALYSIS Advises Life Science Innovators. Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK